Human osteoclasts in vitro are dose dependently both inhibited and stimulated by cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC)

• Published in: Bone (New York, N.Y.) N.Y.), 2024-04, Vol.181, p.117035-117035, Article 117035
• Main Authors: Nielsen, Simone S.R., Pedersen, Juliana A.Z., Sharma, Neha, Wasehuus, Pernille K., Hansen, Morten S., Møller, Anaïs M.J., Borggaard, Xenia G., Rauch, Alexander, Frost, Morten, Sondergaard, Teis E., Søe, Kent
• Format: Article
• Language: English
• Subjects: Bone resorption; Cannabinoids; CBD; Fusion; Osteoclast; THC
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/j.bone.2024.117035

Legalized use of cannabis for medical or recreational use is becoming more and more common. With respect to potential side-effects on bone health only few clinical trials have been conducted – and with opposing results. Therefore, it seems that there is a need for more knowledge on the potential effects of cannabinoids on human bone cells. We studied the effect of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) (dose range from 0.3 to 30 μM) on human osteoclasts in mono- as well as in co-cultures with human osteoblast lineage cells. We have used CD14+ monocytes from anonymous blood donors to differentiate into osteoclasts, and human osteoblast lineage cells from outgrowths of human trabecular bone. Our results show that THC and CBD have dose-dependent effects on both human osteoclast fusion and bone resorption. In the lower dose ranges of THC and CBD, osteoclast fusion was unaffected while bone resorption was increased. At higher doses, both osteoclast fusion and bone resorption were inhibited. In co-cultures, both osteoclastic bone resorption and alkaline phosphatase activity of the osteoblast lineage cells were inhibited. Finally, we observed that the cannabinoid receptor CNR2 is more highly expressed than CNR1 in CD14+ monocytes and pre-osteoclasts, but also that differentiation to osteoclasts was coupled to a reduced expression of CNR2, in particular. Interestingly, under co-culture conditions, we only detected the expression of CNR2 but not CNR1 for both osteoclast as well as osteoblast lineage nuclei. In line with the existing literature on the effect of cannabinoids on bone cells, our current study shows both stimulatory and inhibitory effects. This highlights that potential unfavorable effects of cannabinoids on bone cells and bone health is a complex matter. The contradictory and lacking documentation for such potential unfavorable effects on bone health as well as other potential effects, should be taken into consideration when considering the use of cannabinoids for both medical and recreational use. •10 and 30 μM CBD or THC inhibit human osteoclast differentiation and fusion.•0.3 to 10 μM CBD or THC stimulate bone resorption of human osteoclasts.•In co-cultures, CBD and THC inhibit both human osteoclasts and osteoblasts.•CNR1 and CNR2 are expressed during osteoclastogenesis, but CNR2 is more prominent.•In co-cultures, only CNR2 can be detected in osteoclast and osteoblast nuclei.